News
06-05-2012, 12:11 AM
Celgene International SÃ*rl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.
More... (http://www.news-medical.net/news/20120605/Results-from-Celgenee28099s-ABRAXANE-plus-gemcitabine-clinical-study-on-resectable-pancreatic-cancer.aspx)
More... (http://www.news-medical.net/news/20120605/Results-from-Celgenee28099s-ABRAXANE-plus-gemcitabine-clinical-study-on-resectable-pancreatic-cancer.aspx)